Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs

被引:125
作者
Federici, T. [1 ]
Taub, J. S. [1 ]
Baum, G. R. [1 ]
Gray, S. J. [2 ]
Grieger, J. C. [2 ]
Matthews, K. A. [1 ]
Handy, C. R. [1 ]
Passini, M. A. [3 ]
Samulski, R. J. [2 ]
Boulis, N. M. [1 ]
机构
[1] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA 30322 USA
[2] Univ N Carolina, Ctr Gene Therapy, Chapel Hill, NC USA
[3] Genzyme, Framingham, MA USA
关键词
adeno-associated viral vector; intrathecal; motor neuron; pig; spinal cord; PRECLINICAL SAFETY VALIDATION; MEDIATED GENE-TRANSFER; DORSAL-ROOT GANGLIA; ADENOASSOCIATED VIRUS; CORD; VECTOR; EXPRESSION; THERAPY; BRAIN; MODEL;
D O I
10.1038/gt.2011.130
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Adeno-associated viral vector 9 (AAV9) has recently been shown to penetrate the blood-brain barrier via intravascular administration, making it a good candidate for diffuse gene delivery. However, the potential side effects of systemic delivery are unknown. Intrathecal viral vector administration may be more invasive than intravenous injections, but it requires far less vector and it can be performed on an outpatient basis, making it an ideal route of delivery for clinical translation. A total of 12 domestic farm pigs (<20 kg) underwent a single-level lumbar laminectomy with intrathecal catheter placement for AAV9 delivery. Animals were perfused and the tissue was harvested 30 days after treatment. Gene expression was assessed by anti-green fluorescent protein immunohistochemistry. Although a single lumbar injection resulted in gene expression limited to the lumbar segment of the spinal cord, three consecutive boluses via a temporary catheter resulted in diffuse transduction of motor neurons (MNs) throughout the cervical, thoracic and lumbar spinal cords. We now present the first successful robust transduction of MNs in the spinal cord of a large animal via intrathecal gene delivery using a self-complementary AAV9. These promising results can be translated to many MN diseases requiring diffuse gene delivery.
引用
收藏
页码:852 / 859
页数:8
相关论文
共 49 条
[1]  
Artru AA, 1999, SPINAL DRUG DELIVERY, P177
[2]   Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy [J].
Azzouz, M ;
Le, T ;
Ralph, GS ;
Walmsley, L ;
Monani, UR ;
Lee, DCP ;
Wilkes, F ;
Mitrophanous, KA ;
Kingsman, SM ;
Burghes, AHM ;
Mazarakis, ND .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (12) :1726-1731
[3]   Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intratbecal infusion in pigs [J].
Bernards, Christopher M. .
ANESTHESIOLOGY, 2006, 105 (01) :169-178
[4]  
Beutler AS, 2005, CURR OPIN MOL THER, V7, P431
[5]   Adeno-associated viral vector gene expression in the adult rat spinal cord following remote vector delivery [J].
Boulis, NM ;
Noordmans, AJ ;
Song, DK ;
Imperiale, MJ ;
Rubin, A ;
Leone, P ;
During, M ;
Feldman, EL .
NEUROBIOLOGY OF DISEASE, 2003, 14 (03) :535-541
[6]   Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system [J].
Burger, C ;
Gorbatyuk, OS ;
Velardo, MJ ;
Peden, CS ;
Williams, P ;
Zolotukhin, S ;
Reier, PJ ;
Mandel, RJ ;
Muzyczka, N .
MOLECULAR THERAPY, 2004, 10 (02) :302-317
[7]   Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice [J].
Dominguez, Elisa ;
Marais, Thibaut ;
Chatauret, Nicolas ;
Benkhelifa-Ziyyat, Sofia ;
Duque, Sandra ;
Ravassard, Philippe ;
Carcenac, Romain ;
Astord, Stephanie ;
de Moura, Aurelie Pereira ;
Voit, Thomas ;
Barkats, Martine .
HUMAN MOLECULAR GENETICS, 2011, 20 (04) :681-693
[8]   Intravenous Administration of Self-complementary AAV9 Enables Transgene Delivery to Adult Motor Neurons [J].
Duque, Sandra ;
Joussemet, Beatrice ;
Riviere, Christel ;
Marais, Thibaut ;
Dubreil, Laurence ;
Douar, Anne-Marie ;
Fyfe, John ;
Moullier, Philippe ;
Colle, Marie-Anne ;
Barkats, Martine .
MOLECULAR THERAPY, 2009, 17 (07) :1187-1196
[9]   Results from a phase I safety trial of hAADC gene therapy for Parkinson disease [J].
Eberling, J. L. ;
Jagust, W. J. ;
Christine, C. W. ;
Starr, P. ;
Larson, P. ;
Bankiewicz, K. S. ;
Aminoff, M. J. .
NEUROLOGY, 2008, 70 (21) :1980-1983
[10]   Gene-based treatment of motor neuron diseases [J].
Federici, T ;
Boulis, NM .
MUSCLE & NERVE, 2006, 33 (03) :302-323